Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Masanobu Nakajima & Hiroyuki Kato. (2013) Treatment options for esophageal squamous cell carcinoma. Expert Opinion on Pharmacotherapy 14:10, pages 1345-1354.
Read now
Read now
Maria Albertsson, Lianna Kadar & Magnus Bergenfeldt. (2006) Experiences with the use of oxaliplatin in esophageal carcinoma. Acta Oncologica 45:1, pages 103-105.
Read now
Read now
Anders Ask, Bengt Johansson & Bengt Glimelius. (2005) The potential of proton beam radiation therapy in gastrointestinal cancer. Acta Oncologica 44:8, pages 896-903.
Read now
Read now
Bengt Glimelius. (2003) Acta Oncologica—Greater Attractiveness. Acta Oncologica 42:8, pages 799-799.
Read now
Read now
Mats Talbäck, Magnus Stenbeck, Måns Rosén, Lotti Barlow & Bengt Glimelius. (2003) Cancer Survival in Sweden 1960–1998
Developments Across Four Decades. Acta Oncologica 42:7, pages 637-659.
Read now
Read now
Jae-lyun Lee, Sung-bae Kim, Hwoon-yong Jung, Seung-il Park, Dong-kwan Kim, Jong-hoon Kim, Ho-young Song, Woo-kun Kim, Jung-shin Lee & Young-il Min. (2003) Efficacy of Neoadjuvant Chemoradiotherapy in Resectable Esophageal Squamous Cell Carcinoma. Acta Oncologica 42:3, pages 207-217.
Read now
Read now
Articles from other publishers (14)
Xinfang Lv, Xue Wu, Kai Liu, Xinke Zhao, Chenliang Pan, Jing Zhao, Juan Chang, Huan Guo, Xiang Gao, Xiaodong Zhi, Chunzhen Ren, Qilin Chen, Hugang Jiang, Chunling Wang & Ying‐Dong Li. (2023) Development and validation of a nomogram to predict cardiac death after radiotherapy for esophageal cancer. Cancer Innovation 2:5, pages 391-404.
Crossref
Crossref
Yaping Xu, Xinmin Yu, Qixun Chen & Weimin Mao. (2012) Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?. World Journal of Surgical Oncology 10:1.
Crossref
Crossref
Wei Qu, Wenjuan Li, Ling Wei, Ligang Xing, Xingwu Wang & Jinming Yu. (2010) CIP2A is overexpressed in esophageal squamous cell carcinoma. Medical Oncology 29:1, pages 113-118.
Crossref
Crossref
Stephan Kersting, Ralf Konopke, Dag Dittert, Marius Distler, Felix Rückert, Jörg Gastmeier, Gustavo B Baretton & Hans D Saeger. (2009) Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?. Journal of Gastroenterology and Hepatology 24:5, pages 886-895.
Crossref
Crossref
G. Aaron DuVall, Dino Tarabar, Richard H. Seidel, Nancy L. Elstad & Kirk D. Fowers. (2009) Phase 2: a dose-escalation study of OncoGel (ReGel/paclitaxel), a controlled-release formulation of paclitaxel, as adjunctive local therapy to external-beam radiation in patients with inoperable esophageal cancer. Anti-Cancer Drugs 20:2, pages 89-95.
Crossref
Crossref
Long Sun, Xin-Hui Su, Yong-Song Guan, Wei-Ming Pan, Zuo-Ming Luo, Ji-Hong Wei, Long Zhao & Hua Wu. (2009)
Clinical usefulness of
18
F-FDG PET/CT in the restaging of esophageal cancer after surgical resection and radiotherapy
. World Journal of Gastroenterology 15:15, pages 1836.
Crossref
Crossref
A. Bozikas, W. A. Marsman, W. D. Rosmolen, J. W. P. M. van Baal, W. Kulik, F. J. W. ten Kate, K. K. Krishnadath & J. J. G. H. M. Bergman. (2008) The effect of oral administration of ursodeoxycholic acid and high-dose proton pump inhibitors on the histology of Barrett’s esophagus. Diseases of the Esophagus 21:4, pages 346-354.
Crossref
Crossref
Cuong Duong, Danielle M. Greenawalt, Adam Kowalczyk, Marianne L. Ciavarella, Garvesh Raskutti, William K. Murray, Wayne A. Phillips & Robert J. S. Thomas. (2007) Pretreatment Gene Expression Profiles Can Be Used to Predict Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer. Annals of Surgical Oncology 14:12, pages 3602-3609.
Crossref
Crossref
F. Hagenmüller. (2005) Palliative Therapiemöglichkeiten beim ÖsophaguskarzinomPalliative options for esophageal carcinoma. Der Chirurg 76:11, pages 1044-1052.
Crossref
Crossref
D. Brattström, G. Wagenius, P. Sandström, M. Dreilich, S. Bergström, H. Goike, P. Hesselius & M. Bergqvist. (2005) Newly developed assay measuring cytokeratins 8, 18 and 19 in serum is correlated to survival and tumor volume in patients with esophageal carcinoma. Diseases of the Esophagus 18:5, pages 298-303.
Crossref
Crossref
Makoto Tsuneoka, Kwesi Teye, Nobuyuki Arima, Mikiko Soejima, Hidenori Otera, Kazuyo Ohashi, Yasutoshi Koga, Hiromasa Fujita, Kazuo Shirouzu, Hiroshi Kimura & Yoshiro Koda. (2005) A Novel Myc-target Gene, mimitin, That Is Involved in Cell Proliferation of Esophageal Squamous Cell Carcinoma. Journal of Biological Chemistry 280:20, pages 19977-19985.
Crossref
Crossref
Shinsuke Sato, Yoshiaki Kajiyama, Masahiko Sugano, Yoshimi Iwanuma, Hiroshi Sonoue, Toshiharu Matsumoto, Keisuke Sasai & Masahiko Tsurumaru. (2005) Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. International Journal of Radiation Oncology*Biology*Physics 61:1, pages 203-211.
Crossref
Crossref
Makoto Tsuneoka, Hiromasa Fujita, Nobuyuki Arima, Kwesi Teye, Torahiko Okamura, Hiroki Inutsuka, Yoshiro Koda, Kazuo Shirouzu & Hiroshi Kimura. (2004) Mina53 as a Potential Prognostic Factor for Esophageal Squamous Cell Carcinoma. Clinical Cancer Research 10:21, pages 7347-7356.
Crossref
Crossref
J.-L. Lee, S.I. Park, S.-B. Kim, H.-Y. Jung, G.H. Lee, J.-H. Kim, H.-Y. Song, K.-J. Cho, W.-K. Kim, J.-S. Lee, S.-H. Kim & Y.-I. Min. (2004) A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Annals of Oncology 15:6, pages 947-954.
Crossref
Crossref